BETA
Your AI-Trained Oncology Knowledge Connection!
Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, discuss the evolving treatment landscape for advanced renal cell carcinoma.
EP. 1: Overview of Renal Cell Carcinoma
Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, open the discussion with an overview of renal cell carcinoma.
EP. 2: Renal Cell Carcinoma Histology and Risk Stratification
Experts on renal cell carcinoma describe the RCC histologies and tools used for risk stratification.
EP. 3: Patient Profile: A 67-Year-Old Man With Metastatic Clear Cell RCC
Benjamin Garmezy, MD, presents the case of a 67-year-old man diagnosed with advanced renal cell carcinoma.
EP. 4: Front Line Trials in Advanced RCC
Renal cell carcinoma experts discuss clinical trials, evaluating immunotherapies and tyrosine kinase inhibitors in the front line setting of advanced RCC.
EP. 5: Considerations in Advanced RCC Treatment Selection
Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, outline factors taken into consideration when selecting advanced RCC treatments.
EP. 6: Advanced RCC Treatment Options Post-Progression
Experts on renal cell carcinoma discuss post-progression treatment options for RCC.
EP. 7: TIVO-3 Trial: Tivozanib for Patients With Advanced RCC
A comprehensive overview of the TIVO-3 trial, which compared tivozanib with sorafenib in patients with advanced renal cell carcinoma.
EP. 8: Advanced RCC Treatments Following Prior Immune Checkpoint Inhibitors
Drs Barata and Garmezy give detailed thoughts on treating patients with advanced RCC who have received prior immune checkpoint inhibitors.
EP. 9: Clinical Pearls for Treating Advanced Renal Cell Carcinoma
Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, close their discussion with clinical pearls for community oncologists treating patients with advanced RCC.
Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLC
Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer
SYN818 Shows Favorable Safety Profile in Locally Advanced or Metastatic Solid Tumors
Runimotamab Plus Trastuzumab Is Active and Tolerable in HER2+ Breast Cancer